2020
Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States
Zelenev A, Li J, Shea P, Hecht R, Altice FL. Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States. Clinical Infectious Diseases 2020, 72: 755-763. PMID: 32060534, PMCID: PMC7935393, DOI: 10.1093/cid/ciaa142.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySyringe services programHepatitis C virus (HCV) treatmentC virus treatmentHCV prevalenceHCV microeliminationHCV TasPHCV treatmentPrevention strategiesVirus treatmentTasP strategyHigh HCV prevalenceMicroelimination of HCVHuman immunodeficiency virusHCV treatment coverageOAT coverageAgonist therapyImmunodeficiency virusTreatment coverageMicroeliminationPrevention impactPrevalenceComplimentary interventionsHCVPWIDCo-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes!
Springer SA, Del Rio C. Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes! Clinical Infectious Diseases 2020, 71: 1723-1725. PMID: 32011653, PMCID: PMC7583407, DOI: 10.1093/cid/ciaa111.Peer-Reviewed Original Research
2017
Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study
Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. The Lancet Infectious Diseases 2017, 18: 215-224. PMID: 29153265, PMCID: PMC5860640, DOI: 10.1016/s1473-3099(17)30676-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntiviral AgentsChemopreventionCitiesComputer SimulationDisease Transmission, InfectiousFemaleHepatitis CHumansMaleMiddle AgedModels, StatisticalPrevalenceSubstance Abuse, IntravenousSurveys and QuestionnairesTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsBaseline HCV prevalenceHepatitis C virusHCV prevalenceInjection partnersPrevention strategiesTreatment coverageTransmission of HCVHepatitis C virus (HCV) treatmentHCV elimination strategySuccessful HCV treatmentC virus treatmentInjection drug usersHCV treatment coverageAdditional network memberHCV treatmentActing antiviralsC virusChronic infectionVirus treatmentDrug usersPrevalenceDrug abuseDrugsNational InstitutePrevention
2015
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States
Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clinical Infectious Diseases 2015, 62: 784-791. PMID: 26658053, PMCID: PMC4772845, DOI: 10.1093/cid/civ981.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careVirologic suppressionART costsBudget impactHuman immunodeficiency virus (HIV) treatmentART-naive patientsDTG/ABC/3TCVirologic suppression ratesSubsequent virologic failureCost-effectiveness ratioPerson/yearInitial regimenAntiretroviral therapyInduction regimenNaive patientsVirologic failureAntiretroviral agentsDual therapyHIV infectionTwo-drugDolutegravirVirus treatmentRegimenSurvival rate
2013
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadone
2011
Hepatitis C Virus Treatment in HIV
Chung R, Ketwaroo G. Hepatitis C Virus Treatment in HIV. 2011, 133-139. DOI: 10.1007/978-1-4419-1712-6_15.Peer-Reviewed Original ResearchLiver diseaseHepatitis C virus (HCV) treatmentActive antiretroviral therapyLiver-related mortalityC virus treatmentRate of fibrosisHepatitis C virusHIV coinfectionHIV-HCVAntiretroviral therapyOpportunistic infectionsC virusChronic conditionsVirus treatmentSignificant causeHIVHCVMortalityDiseaseCirrhosisMorbidityComplicationsPatientsFibrosisCoinfection
2006
Rates and predictors of hepatitis C virus treatment in HCV–HIV‐coinfected subjects
BUTT AA, JUSTICE AC, SKANDERSON M, GOOD C, KWOH CK. Rates and predictors of hepatitis C virus treatment in HCV–HIV‐coinfected subjects. Alimentary Pharmacology & Therapeutics 2006, 24: 585-591. PMID: 16907891, DOI: 10.1111/j.1365-2036.2006.03020.x.Peer-Reviewed Original ResearchConceptsHepatitis C virus (HCV) treatmentC virus treatmentHepatitis C virusHepatitis C virus-infected subjectsHCV-HIVVirus-infected subjectsC virusVirus treatmentTreatment ratesVeterans Affairs National Patient Care DatabaseDrug useNational Patient Care DatabaseImpact of comorbiditiesEffect of comorbidityPatient Care DatabaseICD-9 codesCoinfected subjectsHispanic racePharmacy dataBlack raceCare databaseMajor depressionPsychiatric illnessMild depressionBipolar disorder
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply